Immunosuppressant Monitoring-Performance of the First Mass Spectrometry-Based Automated Clinical Analyzer Cascadion

被引:1
|
作者
Grote-Koska, Denis [1 ]
Czajkowski, Stefan [1 ]
Staaden, Antje [1 ]
Brand, Korbinian [1 ]
机构
[1] Hannover Med Sch, Inst Clin Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
immunosuppressants; LC-MS; MS; automated analyzer; CYCLOSPORINE-A; TACROLIMUS; ASSAY;
D O I
10.1097/FTD.0000000000001051
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Automatic analyzers simplify processes and may help improve standardization. The first automated analyzer based on mass spectrometry is available and offers a panel for monitoring cyclosporin A, tacrolimus, sirolimus, and everolimus. Method comparisons and evaluation tests are presented to verify the capability of the Cascadion system for use in a clinical laboratory.Methods:Sample preparation and measurements were performed using the Cascadion clinical analyzer. More than 1000 measurement values of patient samples were compared with an in vitro diagnostic-certified assay run on a liquid chromatography tandem mass spectrometry instrument. Precision and accuracy were determined using commercial quality control and external quality assessment (EQA) samples.Results:A good correlation between the 2 instruments was observed (Pearson correlation r = 0.956-0.996). Deming regression revealed 95% confidence intervals of slopes and intercepts covering the values 1 and 0, for sirolimus and everolimus, respectively, indicating equivalence of both measuring systems. However, for cyclosporin A, a bias was observed and confirmed using a Bland-Altman plot (-9.1%). Measurement repeatability and intermediate measurement precision were appropriate showing coefficients of variation of 0.9%-6.1% and 2.0%-5.3%, respectively. Accuracy according to internal quality controls was 85%-111% and 81%-100% in the EQA samples of Reference Institute of Bioanalytics and Laboratory of the Government Chemist, respectively. High robustness was found with regard to the linearity of the calibration lines (linear regression coefficient r(2) > 0.99). Carryover was negligible (0.1%).Conclusions:The Cascadion automatic analyzer produced convincing results in the measurement of patient, control, and EQA samples. The throughput was sufficient for routine use. Overall, it can be used as an alternative to open liquid chromatography tandem mass spectrometry instruments for immunosuppressant monitoring, simplifying processes without the need for specially trained personnel.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 50 条
  • [21] Recent developments in the technology of mass spectrometry-based clinical proteomics
    Mann, M.
    Cosica, F.
    Kulak, N.
    Pichler, G.
    Tyanova, S.
    Shaman, K.
    Wisniewski, J.
    Cox, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S10 - S10
  • [22] Mass spectrometry-based clinical glycoproteomics for cancer diagnosis and treatment
    Haga, Yoshimi
    CANCER SCIENCE, 2025, 116 : 779 - 779
  • [24] Mass spectrometry-based proteomics as an emerging tool in clinical laboratories
    Alemayehu Godana Birhanu
    Clinical Proteomics, 2023, 20
  • [25] Mass Spectrometry-Based Flavor Monitoring of Peruvian Chocolate Fabrication Process
    Michel, Stephanie
    Baraka, Luka Franco
    Ibanez, Alfredo J.
    Mansurova, Madina
    METABOLITES, 2021, 11 (02) : 1 - 16
  • [26] A fully automated FAIMS-DIA mass spectrometry-based proteomic pipeline
    Reilly, Luke
    Lara, Erika
    Ramos, Daniel
    Li, Ziyi
    Pantazis, Caroline B.
    Stadler, Julia
    Santiana, Marianita
    Roberts, Jessica
    Faghri, Faraz
    Hao, Ying
    Nalls, Mike A.
    Narayan, Priyanka
    Liu, Yansheng
    Singleton, Andrew B.
    Cookson, Mark R.
    Ward, Michael E.
    Qi, Yue A.
    CELL REPORTS METHODS, 2023, 3 (10):
  • [27] Automated Lipid Identification and Quantification by Multidimensional Mass Spectrometry-Based Shotgun Lipidomics
    Yang, Kui
    Cheng, Hua
    Gross, Richard W.
    Han, Xianlin
    ANALYTICAL CHEMISTRY, 2009, 81 (11) : 4356 - 4368
  • [28] Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective
    Qian, Liujia
    Sun, Rui
    Xue, Zhangzhi
    Guo, Tiannan
    MOLECULAR & CELLULAR PROTEOMICS, 2023, 22 (07)
  • [29] Clinical applications of mass spectrometry-based proteomics in cancer: Where are we?
    Boys, Emma L.
    Liu, Jia
    Robinson, Phillip J.
    Reddel, Roger R.
    PROTEOMICS, 2023, 23 (7-8)
  • [30] Mass Spectrometry-Based Tissue Imaging: The Next Frontier in Clinical Diagnostics?
    Leung, Felix
    Eberlin, Livia S.
    Schwamborn, Kristina
    Heeren, Ron M. A.
    Winograd, Nicholas
    Cooks, R. Graham
    CLINICAL CHEMISTRY, 2019, 65 (04) : 510 - 513